Cornell University researchers reported preclinical evidence for GL-4512, an LILRB4 (ILT3) modulator designed to relieve myeloid-driven immune suppression in cancer models. LILRB4 is described as a myeloid checkpoint that contributes to T-cell dysfunction and can drive resistance to immunotherapies across multiple solid and hematologic malignancies. The reported work centers on how modulating LILRB4 can restore immune activity in tumor contexts, offering a potential complement—or alternative—approach to existing checkpoint strategies that primarily target T-cell inhibitory pathways. The finding keeps the LILRB4 axis on the translational map and supports continued exploration of myeloid checkpoint modulation for resistant tumor settings.